Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
G-Protein Coupled Receptor Target Market: By Receptor Type, By Therapeutic Area, By Drug Type, and Geography
G-Protein Coupled Receptor (GPCR) Target Market size was US$ 3,538.5 million in 2023 and is expected to reach US$ 5,391.3 million in 2030, growing at a CAGR of 6.2% during 2024-2030. GPCRs are the largest and most diverse group of membrane receptors in eukaryotes, playing a crucial role in various physiological processes. The market's growth is driven by several factors: increasing prevalence of chronic diseases, rising investment in drug discovery and development, advancements in GPCR research technologies, and the growing focus on personalized medicine. Additionally, the potential of orphan GPCRs as novel drug targets is creating new opportunities for pharmaceutical companies. However, the GPCR targeting market faces challenges such as the complexity of GPCR signalling pathways, high attrition rates in drug development, and the need for more efficient screening technologies.
Study Period
2024-2030Base Year
2023CAGR
6.2%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The GPCR targeting market is experiencing significant growth driven by technological advancements and an increasing understanding of GPCR biology. The emergence of structural biology techniques, such as cryo-electron microscopy, has revolutionized GPCR drug discovery by providing detailed insights into receptor structures and ligand binding mechanisms. This has led to the development of more selective and efficacious GPCR-targeted therapies. Furthermore, the adoption of artificial intelligence and machine learning in drug discovery is accelerating the identification of novel GPCR ligands and potential drug candidates. The market is also seeing a shift towards allosteric modulators and biased agonists, which offer improved safety profiles and reduced side effects compared to traditional orthosteric ligands. Additionally, the growing interest in polypharmacology and multi-target drugs is opening new avenues for GPCR-targeted therapies in complex diseases.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 3,538.5 million |
Market Size in 2030 |
US$ 5,391.3 million |
Market CAGR |
6.2% |
By Receptor Type |
|
By Therapeutic Area |
|
By Drug Type |
|
Download Free Sample Report
The global G-Protein Coupled Receptor (GPCR) Target market size was US$ 3,538.5 million in 2023 and is expected to reach US$ 5,391.3 million in 2030, growing at a CAGR of 6.2% during the forecast period.
Key drivers include the increasing prevalence of chronic diseases, advancements in GPCR research technologies, rising investment in drug discovery and development, and growing focus on personalized medicine.
Restraints include the complexity of GPCR signalling pathways, high attrition rates in drug development, and challenges in developing selective ligands for closely related receptor subtypes.
The major players in the GPCR targeting market include Pfizer Inc., Merck & Co., Inc., Novartis AG, AstraZeneca plc, and Amgen Inc., among others.
1.Executive Summary |
2.Global G Protein Coupled Receptor Target Market Introduction |
2.1.Global G Protein Coupled Receptor Target Market - Taxonomy |
2.2.Global G Protein Coupled Receptor Target Market - Definitions |
2.2.1.Receptor Type |
2.2.2.Therapeutic Area |
2.2.3.Drug Type |
2.2.4.Region |
3.Global G Protein Coupled Receptor Target Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global G Protein Coupled Receptor Target Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global G Protein Coupled Receptor Target Market By Receptor Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Class A |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Class B |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Class C |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global G Protein Coupled Receptor Target Market By Therapeutic Area, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Oncology |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. CNS Disorders |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Cardiovascular Diseases |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Metabolic Disorders |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Immunological Disorders |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Respiratory Diseases |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Others |
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
7.Global G Protein Coupled Receptor Target Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Small Molecules |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Biologics |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8.Global G Protein Coupled Receptor Target Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Receptor Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Class A |
9.1.2.Class B |
9.1.3.Class C |
9.1.4.Others |
9.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oncology |
9.2.2.CNS Disorders |
9.2.3.Cardiovascular Diseases |
9.2.4.Metabolic Disorders |
9.2.5.Immunological Disorders |
9.2.6.Respiratory Diseases |
9.2.7.Others |
9.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Small Molecules |
9.3.2.Biologics |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Receptor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Class A |
10.1.2.Class B |
10.1.3.Class C |
10.1.4.Others |
10.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oncology |
10.2.2.CNS Disorders |
10.2.3.Cardiovascular Diseases |
10.2.4.Metabolic Disorders |
10.2.5.Immunological Disorders |
10.2.6.Respiratory Diseases |
10.2.7.Others |
10.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Small Molecules |
10.3.2.Biologics |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Receptor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Class A |
11.1.2.Class B |
11.1.3.Class C |
11.1.4.Others |
11.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oncology |
11.2.2.CNS Disorders |
11.2.3.Cardiovascular Diseases |
11.2.4.Metabolic Disorders |
11.2.5.Immunological Disorders |
11.2.6.Respiratory Diseases |
11.2.7.Others |
11.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Small Molecules |
11.3.2.Biologics |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Receptor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Class A |
12.1.2.Class B |
12.1.3.Class C |
12.1.4.Others |
12.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oncology |
12.2.2.CNS Disorders |
12.2.3.Cardiovascular Diseases |
12.2.4.Metabolic Disorders |
12.2.5.Immunological Disorders |
12.2.6.Respiratory Diseases |
12.2.7.Others |
12.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Small Molecules |
12.3.2.Biologics |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Receptor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Class A |
13.1.2.Class B |
13.1.3.Class C |
13.1.4.Others |
13.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oncology |
13.2.2.CNS Disorders |
13.2.3.Cardiovascular Diseases |
13.2.4.Metabolic Disorders |
13.2.5.Immunological Disorders |
13.2.6.Respiratory Diseases |
13.2.7.Others |
13.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Small Molecules |
13.3.2.Biologics |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Pfizer Inc. |
14.2.2.Merck & Co., Inc. |
14.2.3.Novartis AG |
14.2.4.AstraZeneca plc |
14.2.5.Amgen Inc. |
14.2.6.Bristol-Myers Squibb Company |
14.2.7.Takeda Pharmaceutical Company Limited |
14.2.8.Sanofi S.A. |
14.2.9.GlaxoSmithKline plc |
14.2.10.Roche Holding AG |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players